Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7475 and Osimertinib in EGFR-mutated NSCLC
NCT06525246Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Jun 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-7475 in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse event. Started Aug 2021; status: completed.
02
Drugs
ONO-7475
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06525246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525246.